Neuphoria Therapeutics Inc.
NEUP
$4.13
-$0.24-5.49%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -13.30K | 15.00M | 662.70K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -13.30K | 15.00M | 662.70K | -- |
| Cost of Revenue | -- | -5.25M | 1.62M | 1.74M | -- |
| Gross Profit | -- | 5.24M | 13.38M | -1.07M | -- |
| SG&A Expenses | 1.87M | 2.07M | 1.41M | 2.63M | 1.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.65M | 5.82M | 3.03M | 4.06M | 3.57M |
| Operating Income | -5.65M | -5.84M | 11.97M | -3.40M | -3.57M |
| Income Before Tax | -9.94M | -9.15M | 11.18M | -1.93M | -937.00K |
| Income Tax Expenses | -34.80K | -266.60K | -81.20K | 11.60K | -132.20K |
| Earnings from Continuing Operations | -9.91M | -8.88M | 11.26M | -1.94M | -804.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.91M | -8.88M | 11.26M | -1.94M | -804.80K |
| EBIT | -5.65M | -5.84M | 11.97M | -3.40M | -3.57M |
| EBITDA | -5.49M | -5.67M | 12.14M | -3.23M | -3.40M |
| EPS Basic | -4.41 | -4.67 | 6.55 | -1.23 | -0.62 |
| Normalized Basic EPS | -2.77 | -3.09 | 4.07 | -0.77 | -0.45 |
| EPS Diluted | -4.41 | -4.67 | 6.55 | -1.23 | -0.62 |
| Normalized Diluted EPS | -2.77 | -3.09 | 4.07 | -0.77 | -0.45 |
| Average Basic Shares Outstanding | 2.25M | 1.90M | 1.72M | 1.58M | 1.30M |
| Average Diluted Shares Outstanding | 2.25M | 1.90M | 1.72M | 1.58M | 1.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |